{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:57:22Z","timestamp":1780549042298,"version":"3.54.1"},"reference-count":46,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea (NRF)","doi-asserted-by":"publisher","award":["NRF-2023M3A9G6057281"],"award-info":[{"award-number":["NRF-2023M3A9G6057281"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>The protozoan parasite Leishmania donovani is the causative agent of visceral leishmaniasis (VL), a potentially fatal disease if left untreated. Given the limitations of current therapies, there is an urgent need for new, safe, and effective drugs. To discover novel antileishmanial compounds from previously unexplored chemical spaces, we conducted a high-throughput screening (HTS) of 2562 natural compounds, assessing their activity against L. donovani promastigotes and intracellular amastigotes. Utilizing the criteria of \u226570% parasite growth inhibition and \u226570% host cell (THP-1) viability, we selected 100 inhibitors for half-maximal inhibitory concentration (IC50) value determination. Twenty-six compounds showed activities in both forms of Leishmania with a selectivity index of over 3. Clustering analysis resulted in four chemical clusters with scaffolds of lycorine (cluster 1), 5-hydroxy-9,10-dihydro-4H,8H-pyrano[2,3-f]chromene-4,8-dione (cluster 2), and semi-synthetic derivatives of ansamycin macrolide (cluster 4). The enantiomer of lycorine, BMD-NP-00820, showed the highest anti-amastigote activity with an IC50 value of 1.74 \u00b1 0.27 \u03bcM and a selectivity index (SI) &gt; 29. In cluster 3, the most potent compound had an IC50 value of 2.20 \u00b1 0.29 \u03bcM with an SI &gt; 23, whereas in cluster 4, with compounds structurally similar to the tuberculosis drug rifapentine, BMD-NP-02085 had an IC50 value of 1.76 \u00b1 0.28 \u03bcM, but the SI value was 7.5. Taken together, the natural products identified from this study are a potential source for the discovery of antileishmanial chemotypes for further development.<\/jats:p>","DOI":"10.3390\/pathogens13030213","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T07:56:02Z","timestamp":1709106962000},"page":"213","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identification of Novel Flavonoids and Ansa-Macrolides with Activities against Leishmania donovani through Natural Product Library Screening"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4696-7490","authenticated-orcid":false,"given":"Trong-Nhat","family":"Phan","sequence":"first","affiliation":[{"name":"Institute of Applied Science and Technology, School of Technology, Van Lang University, Ho Chi Minh City 700000, Vietnam"},{"name":"Faculty of Applied Technology, School of Technology, Van Lang University, Ho Chi Minh City 700000, Vietnam"},{"name":"Host-Parasite Research Laboratory, Discovery Biology, Institut Pasteur Korea, Seongnam-si 13488, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeryon","family":"Lee","sequence":"additional","affiliation":[{"name":"Host-Parasite Research Laboratory, Discovery Biology, Institut Pasteur Korea, Seongnam-si 13488, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hwa","family":"Baek","sequence":"additional","affiliation":[{"name":"Host-Parasite Research Laboratory, Discovery Biology, Institut Pasteur Korea, Seongnam-si 13488, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Hwan","family":"No","sequence":"additional","affiliation":[{"name":"Host-Parasite Research Laboratory, Discovery Biology, Institut Pasteur Korea, Seongnam-si 13488, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024, February 02). Leishmaniasis. Fact Sheet No. 375. Available online: http:\/\/www.who.int\/mediacentre\/factsheets\/fs375\/en\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(98)10178-2","article-title":"Leishmaniasis","volume":"354","author":"Herwaldt","year":"1999","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1471-4922(02)02352-8","article-title":"Interaction of Leishmania with the host macrophage","volume":"18","author":"Handman","year":"2002","journal-title":"Trends Parasitol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0035-9203(00)90055-5","article-title":"Visceral leishmaniasis control: A public health perspective","volume":"94","author":"Boelaert","year":"2000","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_5","unstructured":"(2024, February 02). Parasites\u2013Leishmaniasis, Available online: https:\/\/www.cdc.gov\/parasites\/leishmaniasis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Alvar, J., V\u00e9lez, I.D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., and den Boer, M. (2012). WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035671"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e02851","DOI":"10.7554\/eLife.02851","article-title":"Global distribution maps of the leishmaniases","volume":"3","author":"Pigott","year":"2014","journal-title":"eLife"},{"key":"ref_8","unstructured":"World Health Organization (2010). Control of the Leishmaniasis: WHO TRS No. 949: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22\u201326 March 2010, World Health Organization."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","article-title":"Drug resistance in Indian visceral leishmaniasis","volume":"6","author":"Sundar","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Perry, M.R., Prajapati, V.K., Menten, J., Raab, A., Feldmann, J., Chakraborti, D., Sundar, S., Fairlamb, A.H., Boelaert, M., and Picado, A. (2015). Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: A retrospective cohort study. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003518"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.actatropica.2015.12.016","article-title":"Visceral leishmaniasis: Revisiting current treatments and approaches for future discoveries","volume":"155","author":"No","year":"2016","journal-title":"Acta Trop."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: A comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ponte-Sucre, A., Gamarro, F., Dujardin, J.C., Barrett, M.P., L\u00f3pez-V\u00e9lez, R., Garc\u00eda-Hern\u00e1ndez, R., Pountain, A.W., Mwenechanya, R., and Papadopoulou, B. (2017). Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0006052"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"eaau3174","DOI":"10.1126\/scitranslmed.aau3174","article-title":"Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay","volume":"11","author":"Dziekan","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11101-010-9166-0","article-title":"Artemisinin production in Artemisia annua: Studies in planta and results of a novel delivery method for treating malaria and other neglected diseases","volume":"10","author":"Weathers","year":"2011","journal-title":"Phytochem. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Hobbie, S.N., Kaiser, M., Schmidt, S., Shcherbakov, D., Janusic, T., Brun, R., and B\u00f6ttger, E.C. (2011). Genetic reconstruction of protozoan rRNA decoding sites provides a rationale for paromomycin activity against Leishmania and Trypanosoma. PLoS Negl. Trop. Dis., 5.","DOI":"10.1371\/journal.pntd.0001161"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"953061","DOI":"10.3389\/fitd.2022.953061","article-title":"Drug development for onchocerciasis-the past, the present and the future","volume":"3","author":"Tagboto","year":"2022","journal-title":"Front. Trop. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molcel.2018.08.028","article-title":"Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant Mycobacterium tuberculosis","volume":"72","author":"Mosaei","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Emiliano, Y.S.S., and Almeida-Amaral, E.E. (2023). Apigenin is a promising molecule for treatment of visceral leishmaniasis. Front. Cell Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1066407"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Althaus, J.B., Malyszek, C., Kaiser, M., Brun, R., and Schmidt, T.J. (2017). Alkamides from Anacyclus pyrethrum L. and Their in Vitro Antiprotozoal Activity. Molecules, 22.","DOI":"10.3390\/molecules22050796"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/14786419.2012.696254","article-title":"An antileishmanial prenyloxy-naphthoquinone from roots of Plumbago zeylanica","volume":"27","author":"Mishra","year":"2013","journal-title":"Nat. Prod. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00044-018-2238-1","article-title":"Phytochemical study of Piliostigma thonningii, a medicinal plant grown in Nigeria","volume":"27","author":"Afolayan","year":"2018","journal-title":"Med. Chem. Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Phan, T.N., Baek, K.H., Lee, N., Byun, S.Y., Shum, D., and No, J.H. (2020). In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei. Molecules, 25.","DOI":"10.3390\/molecules25081980"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/1087057114555846","article-title":"High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: Human African trypanosomiasis, leishmaniasis, and Chagas disease","volume":"20","author":"Annang","year":"2015","journal-title":"J. Biomol. Screen."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.3390\/md11104058","article-title":"Trypanocidal activity of marine natural products","volume":"11","author":"Jones","year":"2013","journal-title":"Mar. Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Koko, W.S., Al Nasr, I.S., Khan, T.A., Schobert, R., and Biersack, B. (2022). An Update on Natural Antileishmanial Treatment Options from Plants, Fungi and Algae. Chem. Biodivers., 19.","DOI":"10.1002\/cbdv.202100542"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"579891","DOI":"10.3389\/fchem.2020.579891","article-title":"Use of Natural Products in Leishmaniasis Chemotherapy: An Overview","volume":"8","author":"Gervazoni","year":"2020","journal-title":"Front. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycin for Visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s41467-017-01664-4","article-title":"Atomic resolution snapshot of Leishmania ribosome inhibition by the aminoglycoside paromomycin","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-018-0356-z","article-title":"Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis","volume":"560","author":"Wyllie","year":"2018","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1073\/pnas.1820175116","article-title":"Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition","volume":"116","author":"Wyllie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1021\/acs.jmedchem.1c00047","article-title":"Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis","volume":"64","author":"Thomas","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"16159","DOI":"10.1021\/acs.jmedchem.1c01437","article-title":"DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis","volume":"64","author":"Mowbray","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Najmi, A., Javed, S.A., Al Bratty, M., and Alhazmi, H.A. (2022). Modern Approaches in the Discovery and Development of Plant-Based Natural Products and Their Analogues as Potential Therapeutic Agents. Molecules, 27.","DOI":"10.3390\/molecules27020349"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ja.2014.12","article-title":"Dereplication of microbial extracts and related analytical technologies","volume":"67","author":"Ito","year":"2014","journal-title":"J. Antibiot."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1021\/np50100a001","article-title":"The taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents","volume":"56","author":"Cragg","year":"1993","journal-title":"J. Nat. Prod."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Soto-V\u00e1squez, M.R., Alvarado-Garc\u00eda, P.A.A., Osorio, E.H., Tallini, L.R., and Bastida, J. (2023). Antileishmanial Activity of Clinanthus milagroanthus S. Leiva & Meerow (Amaryllidaceae) Collected in Peru. Plants, 12.","DOI":"10.3390\/plants12020322"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1080\/14786419.2020.1765347","article-title":"Calanolides E1 and E2, two related coumarins from Calophyllum brasiliense Cambess. (Clusiaceae), displayed in vitro activity against amastigote forms of Trypanosoma cruzi and Leishmania infantum","volume":"35","author":"Silva","year":"2021","journal-title":"Nat. Prod. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/ecosalplus.esp-0017-2019","article-title":"Inhibition of RNA Polymerase by Rifampicin and Rifamycin-Like Molecules","volume":"9","author":"Mosaei","year":"2020","journal-title":"EcoSal Plus."},{"key":"ref_43","first-page":"618","article-title":"New World tegumentar leishmaniasis: Chemotherapeutic activity of rifampicin in humans and experimental murine model","volume":"43","author":"Schubach","year":"1995","journal-title":"Pathol. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-4362.1982.tb00517.x","article-title":"Rifampicin treatment of cutaneous leishmaniasis","volume":"21","author":"Weinrauch","year":"1982","journal-title":"Int. J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-4362.1987.tb04578.x","article-title":"Efficacy of rifampicin and isoniazid in cutaneous leishmaniasis","volume":"26","author":"Livshin","year":"1987","journal-title":"Int. J. Dermatol."},{"key":"ref_46","first-page":"240","article-title":"Chemotherapeutic activity of rifampicin on leishmanial amastigotes and promastigotes in vitro","volume":"19","author":"Pearlman","year":"1983","journal-title":"Isr. J. Med. Sci."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/3\/213\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:06:28Z","timestamp":1760105188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/3\/213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["pathogens13030213"],"URL":"https:\/\/doi.org\/10.3390\/pathogens13030213","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]}}}